Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Incyte (INCY) -- Ignore unavailable to you. Want to Upgrade?

To: scaram(o)uche who wrote (2861)	5/16/2013 12:38:36 PM
From: scaram(o)uche	Read Replies (1) \| Respond to of 3202

>> The mucin 1 vaccine that Biomira launched seems to work << The vaccine consists of two independent components, the putative antigen and a new adjuvant, a tlr4 agonist. I therefore can't say "seems to work" in the context of combined use with any immune enhancer, including an ido inhibitor. There is a Merck Kga trial maturing in June that looks at indicators of specific immune response and activation. Maybe I can say more then.